TY - JOUR
T1 - OncoSexome
T2 - The landscape of sex-based differences in oncologic diseases
AU - Shen, Xinyi
AU - Zhang, Yintao
AU - Li, Jiamin
AU - Zhou, Ying
AU - Butensky, Samuel D.
AU - Zhang, Yechi
AU - Cai, Zongwei
AU - Dewan, Andrew T.
AU - Khan, Sajid A.
AU - Yan, Hong
AU - Johnson, Caroline H.
AU - Zhu, Feng
N1 - Funding Information:
National Natural Science Foundation of China [82373790, 22220102001, 81872798 and U1909208]; Natural Science Foundation of Zhejiang Province [LR21H300001]; Fundamental Research Funds for Central Universities [2018QNA7023]; National Key Research & Development Program of China [2022YFC3400501]; Double Top-Class University [181201*194232101]; Key Research & Development Program of Zhejiang [2020C03010]; Westlake Laboratory (Westlake Lab of Life Sciences and Biomedicine); American Cancer Society Research Scholar [134273-RSG-20-065-01 to C.J. and X.S.]; Start-up Grant for New Academics [165520 to Y.H.]. Funds for open access charge: Natural Science Foundation of Zhejiang Province [LR21H300001].
Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.
PY - 2025/1/6
Y1 - 2025/1/6
N2 - The NIH policy on sex as biological variable (SABV) emphasized the importance of sex-based differences in precision oncology. Over 50% of clinically actionable oncology genes are sex-biased, indicating differences in drug efficacy. Research has identified sex differences in non-reproductive cancers, highlighting the need for comprehensive sex-based cancer data. We therefore developed OncoSexome, a multidimensional knowledge base describing sex-based differences in cancer (https://idrblab.org/OncoSexome/) across four key topics: antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF) and microbial landscape (SML). SDR covers sex-based differences in 2051 anticancer drugs; SBM describes 12 551 sex-differential biomarkers; SRF illustrates 350 sex-dependent risk factors; SML demonstrates 1386 microbes with sex-differential abundances associated with cancer development. OncoSexome is unique in illuminating multifaceted influences of biological sex on cancer, providing both external and endogenous contributors to cancer development and describing sex-based differences for the broadest oncological classes. Given the increasing global research interest in sex-based differences, OncoSexome is expected to impact future precision oncology practices significantly.
AB - The NIH policy on sex as biological variable (SABV) emphasized the importance of sex-based differences in precision oncology. Over 50% of clinically actionable oncology genes are sex-biased, indicating differences in drug efficacy. Research has identified sex differences in non-reproductive cancers, highlighting the need for comprehensive sex-based cancer data. We therefore developed OncoSexome, a multidimensional knowledge base describing sex-based differences in cancer (https://idrblab.org/OncoSexome/) across four key topics: antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF) and microbial landscape (SML). SDR covers sex-based differences in 2051 anticancer drugs; SBM describes 12 551 sex-differential biomarkers; SRF illustrates 350 sex-dependent risk factors; SML demonstrates 1386 microbes with sex-differential abundances associated with cancer development. OncoSexome is unique in illuminating multifaceted influences of biological sex on cancer, providing both external and endogenous contributors to cancer development and describing sex-based differences for the broadest oncological classes. Given the increasing global research interest in sex-based differences, OncoSexome is expected to impact future precision oncology practices significantly.
UR - https://www.scopus.com/pages/publications/85214389661
U2 - 10.1093/nar/gkae1003
DO - 10.1093/nar/gkae1003
M3 - Journal article
C2 - 39535034
AN - SCOPUS:85214389661
SN - 0305-1048
VL - 53
SP - D1443-D1459
JO - Nucleic Acids Research
JF - Nucleic Acids Research
IS - D1
ER -
SDG 3 Good Health and Well-being